

Refine Search

Search Results -

Term	Documents
"E.COLI"	9451
E.COLIS	0
(23 AND "E.COLI").PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0
(L23 AND E.COLI).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L24

Refine Search

Recall Text: 

Clear

Interrupt

Search History

DATE: Monday, May 09, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<u>L24</u>	L23 and E.coli	0	<u>L24</u>
<u>L23</u>	L22 and @py<2000	7	<u>L23</u>
<u>L22</u>	L21 and L16	21	<u>L22</u>
<u>L21</u>	method same produce peptide	793	<u>L21</u>
<u>L20</u>	L19 and recombinant	7	<u>L20</u>
<u>L19</u>	L18 and @py<2000	9	<u>L19</u>
<u>L18</u>	L16 and E.coli	35	<u>L18</u>
<u>L17</u>	L16 and E.col	0	<u>L17</u>
<u>L16</u>	atrial natriuretic peptide	1365	<u>L16</u>
<u>L15</u>	L14 and L12	0	<u>L15</u>
<u>L14</u>	methods and recombination	43	<u>L14</u>

<u>L13</u>	L12 and L3	3	<u>L13</u>
<u>L12</u>	natriuretic peptides	1962	<u>L12</u>
<u>L11</u>	atric natriuretic peptides	0	<u>L11</u>
<u>L10</u>	L9 and @py<2000	13	<u>L10</u>
<u>L9</u>	L4 and L7	250	<u>L9</u>
<u>L8</u>	L7 and @py<2000	15	<u>L8</u>
<u>L7</u>	L3 and histidine	278	<u>L7</u>
<u>L6</u>	L4 and @py<2000	19	<u>L6</u>
<u>L5</u>	L4 and o-acetylserine	0	<u>L5</u>
<u>L4</u>	L3 and methionine	285	<u>L4</u>
<u>L3</u>	L2 and E.coli	385	<u>L3</u>
<u>L2</u>	L1 and recombination	5999	<u>L2</u>
<u>L1</u>	protein production	12084	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR-?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 8 May 2005 (20050508/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s method and produce and peptides
2828419 METHOD
1177967 METHODS
3674782 METHOD
(METHOD OR METHODS)
418006 PRODUCE
159962 PRODUCES
562114 PRODUCE
(PRODUCE OR PRODUCES)
240498 PEPTIDES
L1 1421 METHOD AND PRODUCE AND PEPTIDES

=> s atrial natriuretic peptide
23004 ATRIAL
1 ATRIALS
23004 ATRIAL
(ATRIAL OR ATRIALS)
15717 NATRIURETIC
404 NATRIURETICS
15811 NATRIURETIC
(NATRIURETIC OR NATRIURETICS)
328899 PEPTIDE
240498 PEPTIDES
421089 PEPTIDE
(PEPTIDE OR PEPTIDES)
L2 7216 ATRIAL NATRIURETIC PEPTIDE
(ATRIAL (W) NATRIURETIC (W) PEPTIDE)

=> s L1 and L2
L3 7 L1 AND L2

=> s L3 and E. coli
1846798 E
255790 COLI

13 COLIS
255799 COLI
(COLI OR COLIS)
109569 E. COLI
(E(W)COLI)
L4 0 L3 AND E. COLI

=> sd L3 1-7, ibib,abs

SD IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005

L1 1421 S METHOD AND PRODUCE AND PEPTIDES
L2 7216 S ATRIAL NATRIURETIC PEPTIDE
L3 7 S L1 AND L2
L4 0 S L3 AND E. COLI

=> d L3 1-7 ibib,abs

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:740048 CAPLUS

DOCUMENT NUMBER: 141:237094

TITLE: **Methods** and compositions for measuring
biologically active and inactive natriuretic
peptides and for improving their therapeutic
potential

INVENTOR(S): Buechler, Kenneth F.; Whittaker, Michael

PATENT ASSIGNEE(S): Biosite Incorporated, USA

SOURCE: U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S.
Ser. No. 419,059.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 18

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004176914	A1	20040909	US 2003-645874	20030820
US 2003022235	A1	20030130	US 2001-835298	20010413
US 2003109420	A1	20030612	US 2002-139086	20020504
WO 2003016910	A1	20030227	WO 2002-US26604	20020820
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003219734	A1	20031127	US 2003-419059	20030417
JP 2005049351	A2	20050224	JP 2004-238278	20040818
WO 2005019819	A1	20050303	WO 2004-US26984	20040819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-835298	A2 20010413
US 2001-288871P	P 20010504
US 2001-313775P	P 20010820
US 2001-315642P	P 20010828
US 2001-334964P	P 20011130
US 2002-346485P	P 20020102
US 2002-139086	A2 20020504
WO 2002-US26604	A2 20020820
US 2003-419059	A2 20030417
JP 2002-582250	A3 20020411
US 2003-645874	A 20030820
US 2004-542086P	P 20040204

AB The present invention describes compns. and **methods** designed to determine the presence or amount of biol. active natriuretic **peptides**, or their fragments, in a sample. The degradation of natriuretic **peptides** is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can **produce** circulating amts. of natriuretic **peptides** having reduced or lost biol. function. The present invention provides, inter alia, assays designed to accurately measure biol. active natriuretic **peptides**, and compns. to inhibit a previously unknown pathway for degradation of natriuretic **peptides**.

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:405101 CAPLUS

DOCUMENT NUMBER: 137:308521

TITLE: Longstanding atrial fibrillation causes depletion of **atrial natriuretic peptide**

in patients with advanced congestive heart failure
 AUTHOR(S): van den Berg, Maarten P.; Tjeerdsma, Geert; Jan de Kam, Pieter; Boomsma, Frans; Crijns, Harry J. G. M.; van Veldhuisen, Dirk J.

CORPORATE SOURCE: Thorax Center, Department of Cardiology, University Hospital Groningen, Groningen, 9713 GZ, Neth.

SOURCE: European Journal of Heart Failure (2002), 4(3), 255-262

CODEN: EJHFFS; ISSN: 1388-9842

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: Congestive heart failure (CHF) is characterized by neurohormonal activation, including increased plasma concns. of **atrial natriuretic peptide** (ANP) and N-terminal ANP (N-ANP). Onset of atrial fibrillation (AF) further increases these **peptides**, but it may be hypothesized that concns. decrease during longstanding AF due to inherent atrial degeneration. Aim: We sought to investigate the relation between neurohormonal activation in patients with CHF and the duration of concomitant AF. **Methods**: The study group comprised 60 patients (age 70±8 yr) with advanced CHF due to left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) <0.35) and chronic AF (duration 21 (1-340) months). Plasma neurohormone concns. were measured, and multiple regression anal. was performed to identify their

clin. predictors. Results: Median plasma neurohormone concns. were: ANP 113 pmol/l, N-ANP 1187 pmol/l, norepinephrine 496 pg/mL, renin 127 μ units/l, aldosterone 128 pg/mL and endothelin 8.1 pg/mL. Norepinephrine, renin, aldosterone and endothelin were not significantly related to the duration of AF. In contrast, ANP decreased along with the duration of AF ($P=0.03$), while the same trend was observed for N-ANP ($P=0.10$). However, for these peptides a first order interaction with LVEF was present, which was not observed in the other neurohormones. In patients with LVEF >0.25 ANP and N-ANP increased along with the duration of AF, whereas in patients with LVEF ≤ 0.25 an inverse relation between ANP ($P=0.02$) and N-ANP ($P=0.04$) and the duration of AF was present, longer-standing AF being associated with lower concns. Conclusion: In patients with advanced CHF with low LVEF plasma ANP and N-ANP concns. decrease during longstanding AF. This finding agrees with the concept that longstanding AF leads to impaired ability of the atria to produce these neurohormones due to inherent degenerative changes.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:131506 CAPLUS

DOCUMENT NUMBER: 136:199041

TITLE: Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells

INVENTOR(S): Gorman, Cornelia M.; Groskreutz, Debyra J.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: U.S., 65 pp., Cont.-in-part of Appl. No. PCT/US92/10621.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6348327	B1	20020219	US 1993-26143	19930301
WO 9311247	A1	19930610	WO 1992-US10621	19921204
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1099758	A2	20010516	EP 2001-103965	19921204
EP 1099758	A3	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CA 2155434	AA	19940915	CA 1994-2155434	19940301
WO 9420624	A1	19940915	WO 1994-US2233	19940301
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 687301	A1	19951220	EP 1994-909843	19940301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08508398	T2	19960910	JP 1994-520124	19940301
US 2003031654	A1	20030213	US 2001-997868	20011128
PRIORITY APPLN. INFO.:				
			US 1991-803631	B2 19911206
			US 1992-887265	B2 19920522
			WO 1992-US10621	A2 19921204
			EP 1993-900978	A3 19921204
			US 1993-26143	A 19930301
			WO 1994-US2233	W 19940301

AB Provided are animal host cells not naturally capable of forming secretory granules and that produce active, mature insulin by expression of a variant proinsulin containing a non-naturally occurring cleavage site and enzymic cleavage of the non-naturally occurring cleavage site in the host cells. Further provided are methods of culturing such cells.

REFERENCE COUNT: 175 THERE ARE 175 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:145197 CAPLUS
DOCUMENT NUMBER: 134:203411
TITLE: Recombinant secretory cells and their use in
production of human insulin
INVENTOR(S): Newgard, Christopher B.; Halban, Philippe; Normington,
Karl D.; Clark, Samuel A.; Thigpen, Anice E.; Quaade,
Christian; Kruse, Fred
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA;
Betagene, Inc.
SOURCE: U.S., 109 pp., Cont.-in-part of U.S. Ser. No. 589,028.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6194176	B1	20010227	US 1997-785271	19970117
US 6087129	A	20000711	US 1996-589028	19960119
CA 2246268	AA	19970724	CA 1997-2246268	19970117
PRIORITY APPLN. INFO.:			US 1996-589028	A2 19960119

AB The present invention a provides **methods** for production of
heterologous polypeptides, especially insulin, using a variety of recombinant
secretory cell lines, such as neuroendocrine cells and insulinomas. The
common feature of these cell lines is the absence of expression of at
least one endogenous polypeptide. The host cell machinery normally used
to **produce** the endogenous polypeptide is then usurped for the
purpose of making the heterologous polypeptide. Also described are
methods for engineering cells for high-level expression and
methods for large-scale protein production Thus, stable expression of
the human insulin gene in rat insulinoma cells that have had the
endogenous insulin gene insertionally inactivated was demonstrated. These
cells accurately processed the human proinsulin to insulin and secreted
human insulin at the rate of 0.99 µg insulin/106 cells/h. The human
cytomegalovirus immediate early promoter/enhancer and human growth hormone
polyadenylation signals were used to control proinsulin gene expression.

REFERENCE COUNT: 236 THERE ARE 236 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:15390 CAPLUS
DOCUMENT NUMBER: 132:74527
TITLE: **Methods** for production of recombinant
peptides with authentic amino termini
INVENTOR(S): Cottingham, Ian Robert; McKee, Colin Martin; Millar,
Alan Robert
PATENT ASSIGNEE(S): PPL Therapeutics (Scotland) Limited, UK
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000625	A1	20000106	WO 1999-GB1907	19990616

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9943805 A1 20000117 AU 1999-43805 19990616

EP 1090132 A1 20010411 EP 1999-926622 19990616

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

US 2002146779 A1 20021010 US 2000-746945 20001221

PRIORITY APPLN. INFO.: GB 1998-13912 A 19980626

US 1998-98281P P 19980828

WO 1999-GB1907 W 19990616

AB **Methods** for the production of **peptides** with authentic N-termini are provided. The **method** comprises expressing the peptide as part of a fusion protein wherein the peptide sequence incorporates a sequence extension at its N-terminus. The sequence extension may include an protease cleavage site. Alternatively, the sequence extension may include a modified intein, the self-splicing function of which has been disabled. The intein may be the yeast PI-SceI intein or a mini-intein from Mycobacterium tuberculosis recA. The fusion protein may addnl. comprise a label which allows for identification and/or purification of the fusion protein. Transgenic animals which **produce** the desired peptide in their milk are also disclosed..

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:214283 CAPLUS

DOCUMENT NUMBER: 128:280377

TITLE: **Method** for preparing radiolabeled **peptides** using protected polyaminocarboxylate ligands

INVENTOR(S): Srinivasan, Ananthachari

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 5 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5736120	A	19980407	US 1996-660262	19960607

PRIORITY APPLN. INFO.: US 1996-660262 19960607

OTHER SOURCE(S): CASREACT 128:280377; MARPAT 128:280377

AB A **method** is provided for radiolabeling **peptides** using polyaminocarboxylate ligands having suitable protecting groups such that they can be added to **peptides** by standard solid phase or solution phase peptide synthetic chemical and can be deprotected using standard cleavage/deprotection reagents and **produce** the peptide/chelate conjugate as a high purity monoaddn. product is provided. The cleaved and deprotected ligand-peptide mols. can then be labeled with lanthanide or actinide radionuclides. The protected polyaminocarboxylate ligands form mono-anhydrides or mono-active esters under solid phase or solution phase conditions and permit only the desired monoaddn. chelate-peptide conjugate to be formed.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:499250 CAPLUS

DOCUMENT NUMBER: 127:172237

TITLE: Neuroendocrine cell lines for efficient synthesis and secretion of foreign proteins

INVENTOR(S): Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark, Samuel A.; Thigpen, Anice E.; Quaade, Christian; Kruse, Fred; et al.

PATENT ASSIGNEE(S): Board of Regents, University of Texas System, USA; Betagene, Inc.; Newgard, Christopher B.; Halban, Philippe A.; Normington, Karl D.; Clark, Samuel A.; Thigpen, Anice E.

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9726334	A1	19970724	WO 1997-US760	19970117
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6087129	A	20000711	US 1996-589028	19960119
CA 2246268	AA	19970724	CA 1997-2246268	19970117
AU 9718309	A1	19970811	AU 1997-18309	19970117
EP 876484	A1	19981111	EP 1997-903838	19970117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRIORITY APPLN. INFO.: US 1996-589028 A2 19960119
WO 1997-US760 W 19970117

AB **Methods** of constructing neuroendocrine cell lines capable of high-level expression of a foreign gene and efficient secretion of the gene product are described. Such a cell line has lost the ability to express a gene that encodes a major cell gene product specific to the cell line. The host cell machinery normally used to produce this polypeptide then becomes spare production capacity for the synthesis of the foreign gene product. These lines or the gene products have a number of therapeutic uses, e.g. in treatment of disease, in the development of vaccines. The gene may be expressed from a strong animal or animal virus promoter and preferably it is an analog of the major gene inactivated in the development, e.g. a human gene expressed in an insulinoma-derived line. This makes use of the endogenous accessory systems for post-translational modification and secretion of the gene product. Stable expression of the human insulin gene in rat insulinoma cells that have had the endogenous insulin gene insertionally inactivated is demonstrated. These cells also efficiently secreted human insulin and accurately processed the human proinsulin to insulin.

=> d his

(FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005

L1 1421 S METHOD AND PRODUCE AND PEPTIDES

L2 7216 S ATRIAL NATRIURETIC PEPTIDE
 L3 7 S L1 AND L2
 L4 0 S L3 AND E. COLI

=> s Escherichia coli
 235369 ESCHERICHIA
 1 ESCHERICHIAS
 235370 ESCHERICHIA
 (ESCHERICHIA OR ESCHERICHIAS)
 255790 COLI
 13 COLIS
 255799 COLI
 (COLI OR COLIS)
 L5 233445 ESCHERICHIA COLI
 (ESCHERICHIA(W)COLI)

=> s L1 and L3 and L5
 L6 1 L1 AND L3 AND L5

=> d L6

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:15390 CAPLUS
 DN 132:74527
 TI **Methods** for production of recombinant **peptides** with
 authentic amino termini
 IN Cottingham, Ian Robert; McKee, Colin Martin; Millar, Alan Robert
 PA PPL Therapeutics (Scotland) Limited, UK
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000625	A1	20000106	WO 1999-GB1907	19990616
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9943805	A1	20000117	AU 1999-43805	19990616
	EP 1090132	A1	20010411	EP 1999-926622	19990616
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 2002146779	A1	20021010	US 2000-746945	20001221
PRAI	GB 1998-13912	A	19980626		
	US 1998-98281P	P	19980828		
	WO 1999-GB1907	W	19990616		

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1647

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:11:01 ON 09 MAY 2005
FILE 'CAPLUS' ENTERED AT 11:11:01 ON 09 MAY 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.80	41.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	40.80	41.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.11	-5.11

FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005

FILE LAST UPDATED: 6 MAY 2005 (20050506/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s methods and production and recombinant and peptides

2200820 METHODS
350577 PRODUCTION
1812 PRODUCTIONS
351348 PRODUCTION
(PRODUCTION OR PRODUCTIONS)
239919 RECOMBINANT
5553 RECOMBINANTS
242807 RECOMBINANT
(RECOMBINANT OR RECOMBINANTS)
180121 PEPTIDES

L7 216 METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES

```
=> s atrial natriuretic peptide
      81784 ATRIAL
      18750 NATRIURETIC
        18 NATRIURETICS
      18759 NATRIURETIC
          (NATRIURETIC OR NATRIURETICS)
      279999 PEPTIDE
      180121 PEPTIDES
      375755 PEPTIDE
          (PEPTIDE OR PEPTIDES)
L8      7952 ATRIAL NATRIURETIC PEPTIDE
          (ATRIAL (W) NATRIURETIC (W) PEPTIDE)
```

```
=> s L7 and L8
L9      0 L7 AND L8
```

```
=> s natriuretic peptide
      18750 NATRIURETIC
        18 NATRIURETICS
      18759 NATRIURETIC
          (NATRIURETIC OR NATRIURETICS)
      279999 PEPTIDE
      180121 PEPTIDES
      375755 PEPTIDE
          (PEPTIDE OR PEPTIDES)
L10     11030 NATRIURETIC PEPTIDE
          (NATRIURETIC (W) PEPTIDE)
```

```
=> s Escherichia cili
      224164 ESCHERICHIA
        3 ESCHERICHIAS
      224164 ESCHERICHIA
          (ESCHERICHIA OR ESCHERICHIAS)
        15 CILI
        1 CILIS
        16 CILI
          (CILI OR CILIS)
L11     0 ESCHERICHIA CILI
          (ESCHERICHIA (W) CILI)
```

```
=> s Escherichia coli
      224164 ESCHERICHIA
        3 ESCHERICHIAS
      224164 ESCHERICHIA
          (ESCHERICHIA OR ESCHERICHIAS)
      240470 COLI
        5 COLIS
      240472 COLI
          (COLI OR COLIS)
L12     223289 ESCHERICHIA COLI
          (ESCHERICHIA (W) COLI)
```

```
=> d his
```

(FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005

```
L1      1421 S METHOD AND PRODUCE AND PEPTIDES
L2      7216 S ATRIAL NATRIURETIC PEPTIDE
L3      7 S L1 AND L2
L4      0 S L3 AND E. COLI
L5      233445 S ESCHERICHIA COLI
L6      1 S L1 AND L3 AND L5
```

FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005

L7 216 S METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES
L8 7952 S ATRIAL NATRIURETIC PEPTIDE
L9 0 S L7 AND L8
L10 11030 S NATRIURETIC PEPTIDE
L11 0 S ESCHERICHIA CILI
L12 223289 S ESCHERICHIA COLI

=> s L12 and L10 and L7

L13 0 L12 AND L10 AND L7

=> s L7 and L10

L14 0 L7 AND L10

=> s L7 and L10

L15 0 L7 AND L10

=> s L7 and L12

L16 62 L7 AND L12

=> s natriurectic

L17 1 NATRIURECTIC

=> s natriuretic peptide

18750 NATRIURETIC

18 NATRIURETICS

18759 NATRIURETIC

(NATRIURETIC OR NATRIURETICS)

279999 PEPTIDE

180121 PEPTIDES

375755 PEPTIDE

(PEPTIDE OR PEPTIDES)

L18 11030 NATRIURETIC PEPTIDE

(NATRIURETIC(W)PEPTIDE)

=> d his

(FILE 'HOME' ENTERED AT 11:02:36 ON 09 MAY 2005)

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 09 MAY 2005

L1 1421 S METHOD AND PRODUCE AND PEPTIDES

L2 7216 S ATRIAL NATRIURETIC PEPTIDE

L3 7 S L1 AND L2

L4 0 S L3 AND E. COLI

L5 233445 S ESCHERICHIA COLI

L6 1 S L1 AND L3 AND L5

FILE 'MEDLINE' ENTERED AT 11:11:09 ON 09 MAY 2005

L7 216 S METHODS AND PRODUCTION AND RECOMBINANT AND PEPTIDES

L8 7952 S ATRIAL NATRIURETIC PEPTIDE

L9 0 S L7 AND L8

L10 11030 S NATRIURETIC PEPTIDE

L11 0 S ESCHERICHIA CILI

L12 223289 S ESCHERICHIA COLI

L13 0 S L12 AND L10 AND L7

L14 0 S L7 AND L10

L15 0 S L7 AND L10

L16 62 S L7 AND L12

L17 1 S NATRIURECTIC

L18 11030 S NATRIURETIC PEPTIDE

=> s L18 and L16

L19 0 L18 AND L16